Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal



Persistence. Valaciclovir is potentially persistent.

Bioaccumulation. Valaciclovir has low potential for bioaccumulation.

Toxicity. Valaciclovir has low chronic toxicity.

Risk. The use of valaciclovir (sales data Sweden 2019) has been considered to result in insignificant environmental risk.


This summary information comes from Fass.

Detailed information

Fass environmental information

Fass environmental information for Valtrex (valaciclovir) (downloaded 2022-11-29).

"Valaciclovir is a pro-drug which is fully metabolised to the active pharmaceutical ingredient Aciclovir. As a result this assessment is based on aciclovir."


Persistence: "Biotic degradation. Ready degradability: 0.7% degradation in 28 days (TAD 3.11) ... Inherent degradability: 100% primary (loss of parent) degradation in 14 days (OECD 302B). Hydrolysis: Half-life, pH 7 > 1 year (TAD 3.09). Photolysis: Half-life, pH 7 = 3.5 hours (TAD 3.10). Aciclovir is not readily biodegradable nor inherently biodegradable. The phrase “Aciclovir is potentially persistent” is thus chosen."

Bioaccumulation: Log Pcalc = -1.55.

Chronic toxicity: There are data for 3 trophic levels, most sensitive crustacean (Daphnia magna) NOEC > 10 000 microg/L. Comment: Values reported as greater than are not according to the guidelines. The actual value may be lower.


PPEC/PNEC is based on sales data in Sweden in year 2019. PEC/PNEC = 0.00244 which gives the risk insignificant.

Author: Health and Medical Care Administration, Region Stockholm